CD274 and neoplasm: In the IMpower 133 trial, the efficacy of carboplatin and etoposide with atezolizumab, an anti-PD-L1 antibody, was analyzed based on the PD-L1 expression on tumor cells, but there was no difference in the efficacy between patients with PD-L1 expression and those without [1].